BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) and HMC HealthWorks Enter Sales and Distribution Partnership

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, together with HMC HealthWorks, a 40-year veteran in health-care management with clinically-integrated models of care that reduce health-care costs and improve population health, today announced entry into a sales and distribution agreement. Under the partnership, HMC will incorporate DarioHealth’s digital therapeutics solution into its care management programs on a stand-alone basis as well as for incorporation within HMC’s comprehensive solutions. “We believe that this agreement with HMC is further validation of the progress we have made in transitioning to a leading provider of digital-therapeutics solutions to payors, employers and other at-risk entities with a desire to help their members manage their chronic conditions and improve their clinical outcomes,” said Rick Anderson, president and general manager of North America at DarioHealth, in the press release. “We are pleased to partner with HMC, who has a long history of providing innovative solutions to their customers.  This agreement expands our distribution of our solutions, and we are already building a pipeline within HMC’s vast client base, which we believe speaks to the tangible results that we bring to patients and payers alike.”

To view the full press release, visit https://ibn.fm/f9gRq

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, DarioHealth empowers individuals to make adjustments to their daily lifestyle choices to improve their overall health. Its cross-functional team operates at the intersection of life and behavioral sciences and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about the company and its digital health solutions, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies 

Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of…

3 days ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) identifies Biomarker Signature Predicting Sensitivity to IV Sapu003

Oncotelic Therapeutics (OTCQB: OTLC), reports that its 45% owned joint venture, Sapu Nano, has identified…

4 days ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Nu.Q NETs Assay Selected for France’s National Sepsis Detection Initiative

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that its Nu.Q® NETs…

4 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% JV Reports IV Sapu003 Cuts GI Exposure to Everolimus by Up to 67-Fold 

Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic…

5 days ago

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform…

5 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy

Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an…

5 days ago